Re: “Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes” by Sekine et al. ( J. Ocul. Pharmacol. Ther . 2018;34:280–286)
Restricted accessLetterFirst published online July, 2018
Re: “Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes” by Sekine et al. ( J. Ocul. Pharmacol. Ther . 2018;34:280–286)
SekineY., ShimadaM., SatakeS., et al.Pharmacokinetic analysis of intraocular penetration of latanoprost solutions with different preservatives in human eyes. J. Ocul. Pharmacol. Ther., 2018; 34:280–286.
2.
NovackG.D.Pipeline: Thoughts generated by the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. Ocul. Surf., 2:212–214, 2004.
3.
ChambersW.A.Ophthalmic generics: are they really the same. Ophthalmology, 119:1095–1096, 2012.
4.
IchhpujaniP., KatzL.J., HolloG., et al.Comparison of human ocular distribution of bimatoprost and latanoprost. J. Ocul. Pharmacol. Ther., 28:134–145, 2012.
5.
EdererF.Shall we count numbers of eyes or numbers of subjects. Arch. Ophthalmol., 89:1–2, 1973.
6.
DurairajC., ShenJ., and CherukuryM.Mechanism-based translational pharmacokinetic-pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension. Pharm. Res., 31:2095–106, 2014.
